Want to see AU:EZZ full AI Analyst Report?
Top Page
EZZ Life Science Holdings Ltd.
(Sydney:EZZ)
Select Model
Select Model
Rating:66Neutral
Price Target:
AU$0.54
▲(2.88% Upside)
Action:Reiterated
Date:07/21/26
The score is primarily supported by solid underlying profitability and a strong, low-leverage balance sheet, plus attractive valuation (low P/E and high dividend yield). It is meaningfully offset by weak technicals (below key moving averages and negative MACD) and financial risks tied to the recent revenue decline and weaker operating cash flow conversion.
Positive Factors
High Gross Margins
Sustained gross margins above 70% indicate durable product pricing power and favorable unit economics for supplements. High gross margins provide buffer against input cost inflation, support marketing investment and maintain healthy operating margins over the medium term, underpinning cash generation.
Negative Factors
Revenue Decline
A meaningful revenue drop limits scale benefits and signals possible demand weakness or distribution disruption. Over 2-6 months this can compress margins, reduce fixed-cost absorption and weaken bargaining power with platforms or suppliers, challenging durable revenue recovery without strategic action.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margins
Sustained gross margins above 70% indicate durable product pricing power and favorable unit economics for supplements. High gross margins provide buffer against input cost inflation, support marketing investment and maintain healthy operating margins over the medium term, underpinning cash generation.
Read all positive factors
EZZ Life Science Holdings Ltd. (EZZ) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$22.58M
Dividend Yield8.37%
Average Volume (3M)49.70K
Price to Earnings (P/E)7.8
Beta (1Y)1.14
Revenue Growth-18.17%
EPS Growth-70.18%
CountryAU
Employees11
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.06
Shares Outstanding47,043,200
10 Day Avg. Volume67,551
30 Day Avg. Volume49,696
Financial Highlights & Ratios
PEG Ratio-2.50
Price to Book (P/B)3.85
Price to Sales (P/S)1.62
P/FCF Ratio26.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.24
Revenue Forecast (FY)AU$105.10M
EZZ Life Science Holdings Ltd. Business Overview & Revenue Model
Company Description
EZZ Life Science Holdings Limited, an Australian company, specializes in offering a range of skincare and consumer health products, with its market presence extending across Australia, New Zealand, Mainland China, and other international territori...
How the Company Makes Money
EZZ primarily makes money by selling its branded health and wellness products (e.g., supplements/nutraceutical-type consumer health products) to customers and channel partners. Revenue is generated through: (1) Direct-to-consumer sales via online/...
EZZ Life Science Holdings Ltd. Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
80
Positive
Cash Flow
65
Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 61.40M | 66.87M | 66.44M | 37.14M | 15.02M | 22.29M |
| Gross Profit | 41.95M | 49.72M | 50.95M | 27.20M | 7.51M | 12.46M |
| EBITDA | 5.77M | 11.10M | 10.38M | 5.09M | 1.90M | 2.87M |
| Net Income | 2.89M | 6.73M | 6.96M | 3.63M | 1.31M | 2.03M |
Balance Sheet | ||||||
| Total Assets | 32.60M | 33.96M | 25.55M | 17.64M | 14.27M | 12.04M |
| Cash, Cash Equivalents and Short-Term Investments | 13.47M | 20.85M | 19.02M | 13.83M | 10.46M | 8.85M |
| Total Debt | 123.86K | 304.49K | 123.86K | 478.59K | 104.57K | 79.01K |
| Total Liabilities | 4.80M | 5.87M | 4.23M | 3.06M | 2.88M | 1.93M |
| Stockholders Equity | 27.81M | 28.09M | 21.32M | 14.58M | 11.39M | 10.11M |
Cash Flow | ||||||
| Free Cash Flow | -2.69M | 4.09M | 5.73M | 3.91M | 1.89M | 237.42K |
| Operating Cash Flow | -2.62M | 4.35M | 6.14M | 4.01M | 1.90M | 253.53K |
| Investing Cash Flow | -862.95K | -546.93K | -441.17K | -101.78K | -13.18K | -16.12K |
| Financing Cash Flow | -2.20M | -2.17M | -582.45K | -761.72K | -277.36K | 5.44M |
EZZ Life Science Holdings Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | AU$22.58M | 7.83 | 10.35% | 7.80% | -18.17% | -70.18% | |
56 Neutral | AU$63.84M | 65.12 | 17.85% | ― | 38.44% | 230.77% | |
52 Neutral | AU$5.95M | -1.56 | 80.84% | ― | ― | ― | |
52 Neutral | AU$11.62M | -1.93 | -43.95% | ― | 14.30% | 41.93% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$51.95M | -0.41 | -131.13% | ― | 2086.71% | -116.20% | |
41 Neutral | AU$3.16M | -2.50 | -109.45% | ― | ― | 43.14% |
* Healthcare Sector Average
AU:EZZ
EZZ Life Science Holdings Ltd.
0.48
-1.63
-77.40%
AU:ZLD
Zelira Therapeutics
0.50
0.09
21.95%
AU:IMC
Immuron Limited
0.03
-0.04
-52.94%
AU:ANR
Anatara Lifesciences Ltd
0.01
0.00
0.00%
AU:BOT
Botanix Pharmaceuticals Limited
0.02
-0.13
-84.67%
AU:BIO
Biome Australia Ltd
0.29
-0.25
-45.79%
EZZ Life Science Holdings Ltd. Corporate Events
EZZ Life Science Builds Strategic Partnerships as Softer Demand Weighs on Quarterly Cash Flow
Apr 30, 2026
EZZ Life Science reported Q3 FY26 customer receipts of $8.85 million, a 25% decline amid softer demand on major e-commerce platforms, leading to a net operating cash outflow of $3.2 million. The company ended the quarter with $9.96 million in cash...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.